Table 1 Demographics and chemotherapy regimens of sixteen patients with plasma cell disorders and proteasome inhibitor-associated eyelid complications
From: Management and outcomes of proteasome inhibitor associated chalazia and blepharitis: a case series
Patients (n) | 16 |
Average age (range) | 62 (40–82) |
Male (n) | 5 (31%) |
Female (n) | 11 (69%) |
Multiple myeloma isotype (n) | |
IgGa | 10 (71%) |
IgAb | 3 (21%) |
Light Chain | 1 (7%) |
ALc amyloidosis with MGUSd (n) | 2 (12.5%) |
AL amyloid (n) | |
Yes | 4 (25%) |
No | 10 (62.5%) |
Not tested | 2 (12.5%) |
ISSv at diagnosis (median) | 1 |
Complete lines of therapy prior to ocular complication (n) | |
0 | 12 (75%) |
1 | 1 (7%) |
2 | 2 (12.5%) |
3 | 1 (7%) |
Bortezomib exposure (n) | |
Naïve | 12 (75%) |
Previous exposure | 4 (25%) |
Chemotherapy regimen at initial chalazia episode (n) | |
Bortezomib, Lenalidomide, Dexamethasone | 9 (64%) |
Bortezomib, Cyclophosphamide, Dexamethasone | 3 (21%) |
Bortezomib, Dexamethasone | 1 (7%) |
Carfilzomib, Pomalidomide, Dexamethasone | 1 (7%) |
Chemotherapy at initial blepharitis episode (n) | |
Bortezomib, Lenalidomide, Dexamethasone | 6 (60%) |
Bortezomib, Cyclophosphamide, Dexamethasone | 2 (20%) |
Bortezomib, Cyclophosphamide, Pomalidomide, Thalidomide | 1 (10%) |
Carfilzomib, Cyclophosphamide, Dexamethasone | 1 (10%) |
Concurrent steroid use at time of initial complication (n) | 16 (100%) |
Average time to onset of first eyelid complication (range) | 103 days (6–258) |